BioXcel Therapeutics (BTAI) Notes Payables (2017)
BioXcel Therapeutics (BTAI) posted quarterly Notes Payables of $371000.0 for Q4 2017.
BioXcel Therapeutics (BTAI) Notes Payables (2017) Analysis & Trends
BioXcel Therapeutics' Notes Payables history runs 1 years deep, the most recent figure standing at $371000.0 for Q4 2017.
- In Q4 2017, Notes Payables changed N/A year-over-year to $371000.0; the TTM figure through Dec 2017 stood at $371000.0 (changed N/A YoY), while the FY2017 annual figure was $371000.0, changed N/A from the prior year.
- Notes Payables for Q4 2017 stood at $371000.0.
- The five-year high for Notes Payables was $371000.0 in Q4 2017, with the low at $371000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 371,000.00 |